Abstract
Objective To measure the out-of-pocket (OOP) costs of evaluation and management (E/M) services and common diagnostic testing for neurology patients.MethodsUsing a large, privately insured health care claims database, we identified patients with a neurologic visit or diagnostic test from 2001 to 2016 and assessed inflation-adjusted OOP costs for E/M visits, neuroimaging, and neurophysiologic testing. For each diagnostic service each year, we estimated the proportion of patients with OOP costs, the mean OOP cost, and the proportion of the total service cost paid OOP. We modeled OOP cost as a function of patient and insurance factors.ResultsWe identified 3,724,342 patients. The most frequent neurologic services were E/M visits (78.5%), EMG/nerve conduction studies (NCS) (7.7%), MRIs (5.3%), and EEGs (4.5%). Annually, 86.5%-95.2% of patients paid OOP costs for E/M visits and 23.1%-69.5% for diagnostic tests. For patients paying any OOP cost, the mean OOP cost increased over time, most substantially for EEG, MRI, and E/M. OOP costs varied considerably; for an MRI in 2016, the 50th percentile paid $103.10 and the 95th percentile paid $875.40. The proportion of total service cost paid OOP increased. High deductible health plan (HDHP) enrollment was associated with higher OOP costs for MRI, EMG/NCS, and EEG.ConclusionAn increasing number of patients pay OOP for neurologic diagnostic services. These costs are rising and vary greatly across patients and tests. The cost sharing burden is particularly high for the growing population with HDHPs. In this setting, neurologic evaluation might result in financial hardship for patients.
Original language | English (US) |
---|---|
Pages (from-to) | E322-E332 |
Journal | Neurology |
Volume | 96 |
Issue number | 3 |
DOIs | |
State | Published - Jan 19 2021 |
Funding
The study was funded by the American Academy of Neurology Health Services Research Subcommittee. Chloe Hill is supported by NIH KL2TR002241. Evan Reynolds is supported by NIH T32NS0007222. James Burke is supported by R01 AG059733 and R01 MD008879. Mousumi Banerjee has no funding to report. Kevin Kerber is supported by AHRQ R18 HS022258. Brandon Magliocco is an employee of the American Academy of Neurology and has no funding to report. Gregory Esper has no funding to report. Lesli Skolarus is supported by NIH R01 MD008879, U01 AG032947, and R01 MD011516. Brian Callaghan is supported by NIH NIDDK R-01 DK115687 and VA CSRD Merit CX001504. C. Hill, E. Reynolds, J. Burke, M. Banerjee, K. Kerber, and B. Magliocco report no disclosures relevant to the manuscript. G. Esper is on the scientific advisory board for NeuroOne, Inc, a medical device company, and performs medical legal expert consultations. Lesli Skolarus performed consulting for Bracket Global. Brian Callaghan receives research support from the American Academy of Neurology, which supported this project. He consults for a PCORI grant, triages articles and performs evidence-based reviews for DynaMed, and performs medical legal consultations including for the vaccine injury compensation program. Go to Neurology.org/N for full disclosures.
ASJC Scopus subject areas
- Clinical Neurology